Cargando…
Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study
RATIONALE & OBJECTIVE: Individuals with chronic kidney disease frequently suffer from chronic kidney disease-associated pruritus (CKD-aP), impacting sleep quality and quality of life (QoL) and increasing the likelihood of depression. Difelikefalin is a kappa-opioid receptor agonist recently appr...
Autores principales: | Weiner, Daniel E., Vervloet, Marc G., Walpen, Sebastian, Schaufler, Thilo, Munera, Catherine, Menzaghi, Frédérique, Wen, Warren, Bhaduri, Sarbani, Germain, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516453/ https://www.ncbi.nlm.nih.gov/pubmed/36185706 http://dx.doi.org/10.1016/j.xkme.2022.100542 |
Ejemplares similares
-
Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients
por: Fishbane, Steven, et al.
Publicado: (2020) -
Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
por: Topf, Joel, et al.
Publicado: (2022) -
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program
por: Fishbane, Steven, et al.
Publicado: (2022) -
Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
por: Stark, Jeffrey G., et al.
Publicado: (2023) -
Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis
por: Spencer, Robert H., et al.
Publicado: (2023)